The 50,000 Shares of Aerie Pharmaceuticals Inc. (AERI) Stock are sold by Foresite Capital Fund Ii, L.P.

The 50,000 Shares of Aerie Pharmaceuticals Inc. (AERI) Stock are sold by Foresite Capital Fund Ii, L.P.

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) major shareholder Foresite Capital Fund Ii, L.P. sold 50,000 shares of the stock in a transaction on Thursday, October 6th. The stock was sold at an average price of $40.34, for a total value of $2,017,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Foresite Capital Fund Ii, L.P. also recently made the following trade(s): On Friday, July 22nd, Foresite Capital Fund Ii, L.P. acquired 250,000 shares of Aerie Pharmaceuticals stock. The stock was acquired at an average price of $17.50 per share, for a total transaction of $4,375,000.00.

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) opened at 40.49 on Friday. The company’s market capitalization is $1.13 billion. The stock’s 50 day moving average price is $28.57 and its 200-day moving average price is $19.49. Aerie Pharmaceuticals Inc. has a 52 week low of $10.82 and a 52 week high of $41.72.

Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.02. On average, equities research analysts predict that Aerie Pharmaceuticals Inc. will post ($2.81) earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the stock. Barclays PLC increased its stake in shares of Aerie Pharmaceuticals by 3.4% in the second quarter. Barclays PLC now owns 6,015 shares of the company’s stock worth $106,000 after buying an additional 200 shares during the last quarter. First Mercantile Trust Co. acquired a new stake in shares of Aerie Pharmaceuticals during the third quarter worth about $161,000. BlackRock Advisors LLC increased its stake in shares of Aerie Pharmaceuticals by 15.0% in the second quarter. BlackRock Advisors LLC now owns 12,310 shares of the company’s stock worth $217,000 after buying an additional 1,608 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Aerie Pharmaceuticals during the second quarter worth about $219,000. Finally, American International Group Inc. increased its stake in shares of Aerie Pharmaceuticals by 8.5% in the second quarter. American International Group Inc. now owns 13,864 shares of the company’s stock worth $244,000 after buying an additional 1,082 shares during the last quarter. 95.22% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on AERI. Brean Capital reiterated a “buy” rating and issued a $63.00 price objective on shares of Aerie Pharmaceuticals in a research report on Thursday. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 5th. Stifel Nicolaus increased their price objective on Aerie Pharmaceuticals from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 15th. HC Wainwright began coverage on Aerie Pharmaceuticals in a research report on Tuesday, September 20th. They issued a “buy” rating and a $66.00 price objective on the stock. Finally, Raymond James Financial Inc. began coverage on Aerie Pharmaceuticals in a research note on Tuesday, September 13th. They issued an “outperform” rating and a $48.00 target price on the stock. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $51.40.

Aerie Pharmaceuticals Company Profile

Related posts

Leave a Comment